EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Symptom management in isocitrate dehydrogenase mutant glioma

Tobias Walbert iD, Edward K Avila iD, Florien W Boele, Caroline Hertler iD, Christine Lu-Emerson, Pim B van der Meer, Katherine B Peters iD, Alasdair G Rooney iD, Jessica W Templer iD, Johan A F Koekkoek iD

Neuro-Oncology Practice · 06.01.2025 · 12 (Supplement_1) · i38-i48

DOI: 10.1093/nop/npae088 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology Practice, online erschienen am 19.10.2024. Verfasst von Tobias Walbert und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurosurgery, Henry Ford Health, Wayne State and Michigan State University, Detroit, Michigan, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

According to the 2021 World Health Organization classification of CNS tumors, gliomas harboring a mutation in isocitrate dehydrogenase (mIDH) are considered a distinct disease entity, typically presenting in adult patients before the age of 50 years. Given their multiyear survival, patients with mIDH glioma are affected by tumor and treatment-related symptoms that can have a large impact on the daily life of both patients and their caregivers for an extended period of time. Selective oral inhibitors of mIDH enzymes have recently joined existing anticancer treatments, including resection, radiotherapy, and chemotherapy, as an additional targeted treatment modality. With new treatments that improve progression-free and possibly overall survival, preventing and addressing daily symptoms becomes even more clinically relevant. In this review we discuss the management of the most prevalent symptoms, including tumor-related epilepsy, cognitive dysfunction, mood disorders, and fatigue, in patients with mIDH glioma, and issues regarding patient’s health-related quality of life and caregiver needs in the era of mIDH inhibitors. We provide recommendations for practicing healthcare professionals caring for patients who are eligible for treatment with mIDH inhibitors.

Schlagwörter

Stichwörter der Autor:innen

IDH inhibitorepilepsygliomaquality of lifesymptom management

Autor:innen und Institutionen

  • Department of Neurology and Neurosurgery, Henry Ford Health, Wayne State and Michigan State University, Detroit, Michigan, USA.
  • Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Academic Unit of Health Economics, Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, UK.
  • Patient Centred Outcomes Research, Leeds Institute of Medical Research at St. James's, St. James's University Hospital, University of Leeds, Leeds, UK.
  • Competence Center for Palliative Care, Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • Department of Neurology, Maine Health/Maine Medical Center, Scarborough, Maine, USA.

ORCID-Profile: Tobias Walbert, Edward K Avila, Caroline Hertler, Katherine B Peters, Alasdair G Rooney, Jessica W Templer, Johan A F Koekkoek

Förderung

  • NCI NIH HHS

Zitieren

APA

Walbert, T., Avila, E. K., Boele, F. W., Hertler, C., Lu-Emerson, C., van der Meer, P. B., Peters, K. B., Rooney, A. G., Templer, J. W., & Koekkoek, J. A. F. (2025). Symptom management in isocitrate dehydrogenase mutant glioma. Neuro-Oncology Practice, 12(Supplement_1), i38-i48. https://doi.org/10.1093/nop/npae088

Vancouver

Walbert T, Avila EK, Boele FW, Hertler C, Lu-Emerson C, van der Meer PB, et al. Symptom management in isocitrate dehydrogenase mutant glioma. Neuro-Oncology Practice. 2025;12(Supplement_1):i38-i48. doi:10.1093/nop/npae088

BibTeX
@article{Walbert2025,
  author = {Walbert, Tobias and Avila, Edward K and Boele, Florien W and Hertler, Caroline and Lu-Emerson, Christine and van der Meer, Pim B and Peters, Katherine B and Rooney, Alasdair G and Templer, Jessica W and Koekkoek, Johan A F},
  title = {Symptom management in isocitrate dehydrogenase mutant glioma},
  journal = {Neuro-Oncology Practice},
  year = {2025},
  volume = {12},
  number = {Supplement_1},
  pages = {i38--i48},
  doi = {10.1093/nop/npae088}
}
Kostenlos starten →